Subscribe To
SLGL / 3 Generic Drug Stocks to Watch Amid Inflation Pressures
SLGL News
By Zacks Investment Research
August 10, 2023
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. more_horizontal
By Zacks Investment Research
May 12, 2023
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22. more_horizontal
By Zacks Investment Research
December 7, 2022
3 Generic Drug Stocks to Watch Amid Inflation Pressures
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some re more_horizontal
By Zacks Investment Research
November 10, 2022
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. more_horizontal